Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Jeeha Park, Rachel Murphy

St. George’s University School of Medicine. Grenada

Title: Low-Dose Naltrexone in treating Fibromyalgia and Major Depressive Disorder

Biography

Biography: Jeeha Park, Rachel Murphy

Abstract

Low-dose naltrexone (LDN) can modulate CNS microglial cells and is being used as an experimental treatment to reduce inflammatory autoimmune processes in a number of diseases, including fibromyalgia. Additionally, LDN has been shown to demonstrate antidepressant effects by enhancing dopaminergic signaling. These mechanism suggests LDN as a possible concurrent treatment of both fibromyalgia and associated major depressive disorder. Fibromyalgia is considered a chronic disorder of central nervous system pain regulation. It is an inflammatory rheumatic disease that presents as widespread musculoskeletal pain and stiffness. Fibromyalgia does not have a clear pathogenesis and consequently does not have a targeted treatment. Chronic pain and major depressive disorder are often diagnosed simultaneously; 40-60% of chronic pain patients also have depression and require concurrent treatment. There is no direct cause-and-effect relationship between chronic pain and depression; however, two illness share many biochemical, physical and cognitive symptoms. J.B. is a 32 year old Caucasian female with a past psychiatric history of major depressive disorder, generalized anxiety disorder and panic attacks and medical history of fibromyalgia diagnosed in 2010. Patient has recurring depressive episodes with multiple etiologies including problems with her family and work and post-partum. However, many of the depressive episodes concurred with painful symptoms of her fibromyalgia and “dictated by the pain level.” Patient’s fibromyalgia and major depressive disorder did not respond to duloxetine. There was significant symptomatic relief of both chronic pain and depression with the initiation of 6mg naltrexone. Patient reported improvements in mood, energy, and concentration from suboptimal level. We discuss the indications of this case and future possibility of using LDN as a treatment option for patients with concurrent fibromyalgia and major depressive disorder.